O-045: Analysis of the Efficacy and Safety of Daclatasvir and Asunaprevir in Korean Genotype 1b Chronic Hepatitis C Patients

Aims: HCV genotype 1 has been known to be the most common and difficult to treat genotype worldwide under the treatment of pegylated interferon and ribavirin. The enhanced antiviral activity achieved by combining two direct-acting antiviral (DAA) agents, daclatasvir and asunaprevir, has been studied and represent the treatment of choice in this population. However, there is a lack of real-world data of the treatment efficacy and safety of the combined drug in Korean patients. Methods: A total of 126 HCV genotype 1b patients treated with daclatasvir 60mg once daily and asunaprevir 100mg twice daily for 24 weeks were retrospectively reviewed from 4 centers of the Gwang-Ju/Jeon Nam province from August 2015 to April 2016. The treatment efficacy (HCV RNA 200 U/L) was noted in patient (0.8%). Fatigue (10.3%), headache (6.34%), nausea (4.7%), asthenia (3.2%) and diarrhea (0.8%) were noted but did not lead to discontinuation of therapy. Conclusions: In HCV genotype 1b infected patients in Korea, Daclatasvir plus asunaprevir is well tolerated and provide high sustained virologic response. Studies to establish the predicting factors related to treatment response is further required.